---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096177"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:40:33.440026+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q2 2024: Cash $352M; FT819 SLE study adds Cy; FT522 first patient without conditioning

## Summary
- Cash, equivalents & investments $352.0M; projected operating runway through YE26.
- Revenue $6.8M (incl. $5M milestone from Ono); GAAP operating expenses $51.9M (R&D $34.6M, G&A $17.3M).
- FT819 Phase 1 SLE study: first patient (lupus nephritis) dosed; protocol amended to include single-agent cyclophosphamide; no Grade≥3 AEs, no CRS/ICANS/GvHD.
- FT825/ONO-8250 Phase 1 solid tumor study: three patients treated as monotherapy; combo dosing with mAb expected 3Q24.
- FT522 Phase 1 BCL study: first patient treated without conditioning chemotherapy at 300M cells/dose; IND for autoimmune basket study planned 3Q24.

## SEC filing metadata
- accession: 0000950170-24-096177
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017024096177/0000950170-24-096177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017024096177/fate-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096177
- JSON: https://secwatch.observer/filing/0000950170-24-096177.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.